Home / Research Library / REGENESIS · Cellular and Tissue-Model Research
REGENESIS · Cellular and Tissue-Model Research

The Wolverine Stack Explained: BPC-157 + TB-500

2026-06-08 · ~4 min read · For laboratory and educational use only

All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.

The short version
  • The Wolverine stack is a nickname for combining two recovery-research peptides, BPC-157 and TB-500, studied together for tissue repair.
  • The research is mostly preclinical (animal) with limited human trials, so recovery claims are not proven in people.
  • The nickname and routines come from online recovery communities, which are unverified anecdotes, not controlled data.
  • Neither compound is approved for human or veterinary use, and nothing here is medical advice or dosing.
  • BioRegen sells these strictly for laboratory and educational research.

"Wolverine stack" is a nickname people in research-peptide circles use for putting two repair-related peptides together: BPC-157 and TB-500 (a piece linked to a molecule called Thymosin beta-4). All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice. This article explains what the pair is, what published research has looked at for each peptide on its own, how far along that research is, and how labs handle these materials.

What the Wolverine stack combines

The stack means two separate research peptides studied next to each other. BPC-157 is a man-made peptide built from 15 amino acid building blocks. Its sequence was first found in stomach fluid. TB-500 is a man-made peptide tied to one active part of Thymosin beta-4, a repair-related peptide the body makes on its own. Calling it a "stack" simply means that some lab work studies the two peptides together instead of one at a time. BioRegen sells these as reference materials for lab and test-tube study only. To compare related research compounds, see our research finder.

What the research explores: mechanisms

In studies listed on PubMed, BPC-157 has been looked at in animals and in test tubes for a possible link to the growth of new blood vessels (called angiogenesis) and to repair of soft tissue, including tendon, ligament, and muscle models. Separately, research has described Thymosin beta-4 (the larger molecule that the TB-500 piece comes from) as a peptide studied for its part in helping cells move, in calling up repair cells, and in dialing down inflammation and scarring. Researchers who study the pair think the two might work in ways that support each other, but there are no careful human studies that compare the combination head to head.

Research stage and limitations

It helps to be clear about how strong the evidence is. Most published BPC-157 work uses small animals like rats and mice, and review articles point out that it has not been shown to work in people. Thymosin beta-4 has been studied more broadly, and the natural peptide has had some early human studies for things like skin wounds and eye-surface wounds. But TB-500 itself is a research piece, not an approved medicine. Neither compound is approved for human or animal use. Talk about the stack in online communities is made up of personal stories that have not been checked, not careful studies, and BioRegen does not make or back any claims based on them.

Laboratory handling notes

Freeze-dried research peptides are usually kept cold and out of the light. Many labs store unmixed vials in the fridge or freezer and try not to thaw and refreeze them over and over. For test-tube work, researchers mix the powder back into liquid using bacteriostatic or sterile water with clean, germ-free handling, then keep the mixed material in the fridge and use it within a set time. For a general look at how this mixing is done in a lab setting, see our guide on how to reconstitute peptides. Always follow your own lab's safety rules and the certificate-of-analysis paperwork.


Frequently asked questions

Why are BPC-157 and TB-500 grouped as a "stack"?

It is just a nickname from the research community, used because some lab work studies the two repair-related peptides together. It is only a name. It does not say anything about whether they work or whether they are safe.

Is TB-500 the same as Thymosin beta-4?

No. TB-500 is a man-made piece tied to one active part of Thymosin beta-4. A lot of the published research is about the full Thymosin beta-4 peptide, so researchers should not assume those findings carry straight over to the smaller piece.

Are these compounds approved for use?

No. Neither BPC-157 nor TB-500 is approved for human or animal use. They are sold only as reference materials for lab and educational research.

Continue your research

For background on how studies are set up and where to get reference materials, read our research guide, and create a free account for 10% off your first order. To see the reference materials in this category, browse the Regenesis research peptides collection. If you are comparing weight and metabolism compounds, our retatrutide vs tirzepatide vs semaglutide overview may also help.

Selected research references

Reference metadata sourced via PubMed.

Disclaimer: All information on this page is provided for laboratory and educational research purposes only. No compound referenced is approved for human or veterinary use, and nothing here constitutes medical advice or a claim to diagnose, treat, cure, or prevent any disease. Any anecdotal mentions are unverified reports, not controlled findings, and BioRegen does not make or endorse claims based on them.

Community & anecdotal, unverifiedWhat is being discussed right now. The "Wolverine stack" (the pairing of BPC-157 with TB-500) is currently one of the most-discussed recovery combinations in biohacker and longevity communities, athletic and strength-training circles, and among compounding-pharmacy and wellness-clinic operators who market it for soft-tissue and joint recovery. Much of the public conversation lives in peptide-focused content sites, vendor research guides (brands such as Spartan Peptides and Moonshot have published stack overviews), clinic blogs offering it as a paid therapy, and longform commentary venues like Substack newsletters covering tissue-repair peptides. A recurring theme in these discussions is that the "synergy" rationale is mechanistic and theoretical: commenters and reviewers note that no controlled trial has compared the combination against either compound alone, that published human data on BPC-157 is limited to a few small studies, and that TB-500 has no published human trials. Discussion intensified in early 2026 around reports that U.S. regulators outlined a pathway for a set of peptides, said to include BPC-157 and TB-500, to be compounded by licensed pharmacies under prescription; participants widely caution that such a pathway is not an FDA finding of safety or efficacy. These are unverified anecdotal reports and current discussion, not controlled findings, and not BioRegen claims.
In the catalog

Shop these research materials

Related research

More peptide research to explore

Explore the research line

Browse the BioRegen catalog, or grab the free reference guide · create a free account for 10% off your first order.